Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D36JFT
|
|||
| Drug Name |
ARV-1801
|
|||
| Synonyms |
ACG-701
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Melioidosis [ICD-11: 1C42] | Phase 2 | [1] | |
| Company |
Arrevus
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein synthesis (hPRO synth) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05105035) A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.